Published in
Wiley, Angewandte Chemie International Edition, 38(52), p. 10006-10009, 2013
Wiley, Angewandte Chemie, 38(125), p. 10190-10193, 2013
Links
Tools
Steering Target Selectivity and Potency by Fragment-Based De Novo Drug Design
Journal article published in 2013 by
Tiago Rodrigues,
Takayuki Kudoh,
Filip Roudnicky,
Yi Fan Lim,
Yen-Chu Lin,
Christian P. Koch,
Masaharu Seno 
,
Michael Detmar,
Gisbert Schneider
,
Michael Detmar,
Gisbert Schneider
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Kinase inhibitors: Ligand-based de novo design is validated as a viable technology for rapidly generating innovative compounds possessing the desired biochemical profile. The study discloses the discovery of the most selective vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor (right in scheme) known to date as prime lead for antiangiogenic drug development.